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Abstract
Following an application from DSM Nutritional Products, submitted for authorisation of a health claim
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the United
Kingdom, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an
opinion on the scientiﬁc substantiation of a health claim related to docosahexaenoic acid (DHA) and
improvement of memory function. DHA is sufﬁciently characterised. An improvement of memory
function is a beneﬁcial physiological effect. In weighing the evidence, the Panel took into account that,
out of the 11 human intervention studies from which conclusions can be drawn for the scientiﬁc
substantiation of the claim, two studies showed a beneﬁcial effect of DHA supplementation on memory
function, one study showed inconsistent results, one study showed a negative effect of DHA on
memory function and seven studies did not show an effect of DHA on memory outcomes. The
Panel considers that the majority of the human intervention studies provided did not show an effect of
DHA supplementation on memory, and that the conﬂicting results across studies cannot be explained
by differences in the study design, the source of DHA, the DHA dose, the baseline characteristics of
the subjects recruited, or the duration of the studies. The Panel also took into account that the meta-
analyses of intervention studies submitted by the applicant do not provide evidence for an effect of
DHA on memory function, and that the three observational studies from which conclusions could be
drawn for the scientiﬁc substantiation of the claim do not provide evidence for an association between
dietary DHA and memory function. The Panel concludes that a cause and effect relationship has not
been established between the consumption of DHA and an improvement of memory function.
© 2016 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following an application from DSM Nutritional Products, submitted for authorisation of a health
claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the
United Kingdom, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to
deliver an opinion on the scientiﬁc substantiation of a health claim related to docosahexaenoic acid
(DHA) and improvement of memory function.
The scope of the application was proposed to fall under a health claim based on newly developed
scientiﬁc evidence.
The food constituent that is the subject of the health claim is DHA (22:6 n-3) which is a
well-characterised n-3 long-chain polyunsaturated fatty acid. The Panel considers that DHA is
sufﬁciently characterised.
The claimed effect proposed by the applicant is ‘contributes to improved memory function’. The
target population proposed by the applicant is ‘the general healthy adult population’. Memory is the
cognitive ability to maintain previously learned information, so that it may be accessed and used
at a later time. Memory is not a unitary construct but instead reﬂects a number of distinct
cognitive processes (e.g. episodic memory, working memory, short-term memory, semantic
memory). The Panel considers that an improvement of memory function is a beneﬁcial
physiological effect.
The applicant identiﬁed 15 human intervention studies and 13 observational studies as being
pertinent to the claim. The applicant also provided three meta-analyses using data from the
15 intervention studies.
No conclusions could be drawn from four out of the 15 human intervention studies owing to
methodological limitations. Out of the 11 intervention studies from which conclusions could be drawn
for the scientiﬁc substantiation of the claim, two were performed with DHA from microalgae, eight
with DHA from ﬁsh oil and one with phosphatidylserine (PS)-DHA. One study conducted with DHA
from algal oil showed an improvement in episodic memory but not in working memory in healthy
older adults with age-related cognitive decline after consumption of 900 mg DHA for 24 weeks, while
the other study with DHA from the same source showed a negative effect on episodic memory and
no effect on semantic memory in young adults after consumption of 400 mg DHA for 50 days. Out
of the eight intervention studies performed with DHA from ﬁsh oil, which provided daily doses of
DHA ranging from 252 mg to 1.55 g for periods between 12 weeks and 24 months, only one
showed an improvement in memory in adults with mild cognitive impairment, while the results from
another study were inconsistent and six studies did not show an effect of DHA supplementation on
memory outcomes. The study which used PS-DHA did not show an effect of the food on memory
function.
The applicant conducted meta-analyses using data from the 15 intervention studies. The overall
between-group models, which included all dose levels of DHA, all sources of DHA, and all subjects
regardless of their age or cognitive status at baseline, showed no effect of DHA supplementation on
episodic, semantic or working memory. The Panel considers that these meta-analyses do not provide
evidence for an effect of DHA on memory function.
The applicant provided 13 observational studies as being pertinent to the claim. Among the
references provided, nine studies did not report on dietary intakes of DHA but addressed the
association between blood concentrations of DHA and measures of memory. One study reported only a
composite cognitive score but no independent memory test scores. No conclusions can be drawn from
these 10 studies for the scientiﬁc substantiation of the claim. The three remaining observational
studies from which conclusions can be drawn for the scientiﬁc substantiation of the claim did not
provide evidence for an association between dietary DHA and memory function.
In weighing the evidence, the Panel took into account that, out of the 11 human intervention
studies from which conclusions can be drawn for the scientiﬁc substantiation of the claim, two
studies showed a beneﬁcial effect of DHA supplementation on memory function, one study showed
inconsistent results, one study showed a negative effect of DHA on memory function and seven
studies did not show an effect of DHA on memory outcomes. The Panel considers that the majority
of the human intervention studies provided did not show an effect of DHA supplementation on
memory, and that the conﬂicting results across studies cannot be explained by differences in the
study design, the source of DHA, the DHA dose, the baseline characteristics of the subjects recruited
or the duration of the studies. The Panel also took into account that the meta-analyses of
intervention studies submitted by the applicant do not provide evidence for an effect of DHA on
DHA and improvement of memory function
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memory function, and that the three observational studies from which conclusions could be drawn
for the scientiﬁc substantiation of the claim do not provide evidence for an association between
dietary DHA and memory function.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of DHA and an improvement of memory function.
DHA and improvement of memory function
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and speciﬁc requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this
Regulation lays down provisions for the addition of claims (other than those referring to the reduction
of disease risk and to children’s development and health) which are based on newly developed
scientiﬁc evidence, or which include a request for the protection of proprietary data, to the Community
list of permitted claims referred to in Article 13(3).
According to Article 18 of this Regulation, an application for inclusion in the Community list of
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national
competent authority of a Member State, which will make the application and any supplementary
information supplied by the applicant available to the European Food Safety Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientiﬁc data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientiﬁc substantiation of a health claim related to: docosahexaenoic acid (DHA) and
improvement of memory function.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of DHA, a positive assessment of its safety, nor a decision on whether DHA is, or is not,
classiﬁed as a foodstuff. It should be noted that such an assessment is not foreseen in the framework
of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
1.3. Additional information
Claims on DHA and maintenance of normal brain function (EFSA NDA Panel, 2010) and contribution
to normal brain development (EFSA NDA Panel, 2014) have already been assessed by the Panel with
favourable outcomes.
2. Data and methodologies
2.1. Data
2.1.1. Information provided by the applicant
Food/constituent as stated by the applicant:
• According to the applicant, the food which is the subject of the health claim is DHA.
Health relationship as claimed by the applicant:
• According to the applicant, DHA contributes to improved memory function.
• The applicant states that this improvement of memory function could be assessed by
improvements in tests of episodic memory following DHA supplementation from a variety of
sources.
• With regard to a possible mechanism, the applicant claims that DHA has been shown to
enhance neurotransmission via increased synaptic plasticity of the glutamatergic synapses in
the hippocampus and pre-frontal cortex, to protect the glutamatergic synapses via regulation
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
DHA and improvement of memory function
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of astrocyte function and plasticity, and to support adult neurogenesis by maintaining active
proliferative pools and favouring neuronal maturation.
Wording of the health claim as proposed by the applicant:
• ‘DHA contributes to improved memory function’.
Speciﬁc conditions of use as proposed by the applicant:
• The applicant has proposed an intake of ≥ 580 mg DHA/day. According to the applicant, this
level of daily intake could be obtained from conventional foods, fortiﬁed foods, food
supplements or a combination of these.
• The target population proposed by the applicant is the general healthy adult population.
2.1.2. Data provided by the applicant
Health claim application on DHA, alone or in combination with eicosapentaenoic acid (EPA),
contributes to improved memory function pursuant to Article 13.5 of Regulation 1924/2006, presented
in a common and structured format as outlined in the Scientiﬁc and technical guidance for the
preparation and presentation of applications for authorisation of health claims (EFSA NDA Panel, 2011).
As outlined in the EFSA general guidance for stakeholders on health claim applications (EFSA NDA
Panel, 2016), it is the responsibility of the applicant to provide the totality of the available evidence.
2.2. Methodologies
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in
the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016).
The scientiﬁc requirements for health claims related to functions of the nervous system, including
psychological functions, are outlined in a speciﬁc EFSA guidance (EFSA NDA Panel, 2012).
3. Assessment
3.1. Characterisation of the food/constituent
The food constituent that is proposed by the applicant as the subject of the health claim is DHA
(22:6 n-3).
In the original application, the food was speciﬁed as ‘DHA, alone or in combination with EPA’.
Following an EFSA request for clariﬁcation, the applicant indicated that DHA is the food which is the
subject of the health claim.
DHA is a well-characterised n-3 long-chain polyunsaturated fatty acid (LCPUFA) that can be
quantiﬁed in foods by established methods. The absorption of DHA is well documented. This
evaluation applies to all sources of DHA in the speciﬁed amounts.
The Panel considers that the food constituent, DHA, which is the subject of the health claim, is
sufﬁciently characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘contributes to improved memory function’. The
target population proposed by the applicant is ‘the general healthy adult population’.
Memory is the cognitive ability to maintain previously learned information, so that it may be
accessed and used at a later time. Memory is not a unitary construct but instead reﬂects a number of
distinct cognitive processes (e.g. episodic memory, working memory, short-term memory, semantic
memory).
The improvement, maintenance or reduced loss of one or more cognitive processes related to
memory is considered to be a beneﬁcial physiological effect (EFSA NDA Panel, 2012).
Changes in different aspects of memory (e.g. episodic memory, working memory, short-term
memory, semantic memory) can be measured in vivo in humans using valid psychometric tests.
The Panel considers that an improvement of memory function is a beneﬁcial physiological effect.
DHA and improvement of memory function
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3.3. Scientiﬁc substantiation of the claimed effect
The applicant performed a literature search in Ovid/Medline and Embase through January 2013.
Relevant terms representing DHA and EPA (as well as their dietary sources) and memory were used.
Hand searching was carried out by examining the reference lists of all relevant studies, pertinent
review articles and meta-analyses. The literature searches were repeated in September 2014 to
identify any recently published trials. Studies were included if they were controlled clinical trials
(randomised and non-randomised) or observational studies and assessed the effect of DHA intake,
either alone or in combination with EPA, from conventional or fortiﬁed sources (foods or food
supplements), on memory outcomes in healthy adults residing in the community at baseline (includes
assisted living facilities, but excludes long-term care nursing facilities), with or without mild memory
complaints. Studies were excluded if: (a) intakes of DHA and/or EPA were not reported; (b) they were
carried out in subjects with current diagnosis of Alzheimer’s disease (AD), dementia, vascular
dementia, stroke, head injury, substance abuse, metabolic disturbance, depression, behavioural or
neurologic disorder; (c) included subjects with group mean baseline mini-mental state examination
(MMSE) scores < 24 (indicative of advanced cognitive decline/AD); (d) more than 10% of the subjects
were on psychotropic, antidepressant, stimulant or drugs approved for the treatment of AD/dementia.
The applicant identiﬁed 15 human intervention studies and 13 observational studies as being
pertinent to the claim. The applicant also provided three meta-analyses using data from the
15 intervention studies.
3.3.1. Human intervention studies
One of the human intervention studies provided (Richter et al., 2010) was a single-arm trial (i.e. no
control group) on the effects of phosphatidylserine (PS) with DHA and EPA on episodic and working
memory. The Panel considers that no conclusions can be drawn from this uncontrolled study for the
scientiﬁc substantiation of the claim.
Johnson et al. (2008) conducted a double-blind, randomised controlled trial (RCT) on the effects of
DHA (from microalgae) and/or lutein consumed for 4 months on episodic memory, working memory,
short-term memory and semantic memory in 57 women aged between 60 and 80 years. Within-group
differences between memory scores at baseline and after supplementation were tested with paired
t-tests. Between-group comparisons were not reported. The applicant was requested to provide a
statistical analysis of the data which is appropriate for placebo-controlled designs, i.e. an analysis
which tests differences in changes among the study arms over time for the memory outcomes
measured. Such an analysis was not provided by the applicant. The Panel considers that no
conclusions can be drawn from this study for the scientiﬁc substantiation of the claim.
Kotani et al. (2006) studied the effects of DHA in combination with arachidonic acid (ARA) on
episodic memory, semantic memory and short-term memory in patients with mild cognitive impairment
(MCI), organic brain lesions and AD. A total of 21 patients (12 male, 9 female, mean
age = 61.8 years) with MCI were randomly allocated to receive daily 240 mg DHA in combination with
240 mg ARA (both contained in a food supplement) or 240 mg placebo. A group of 10 patients with
organic brain lesions and eight patients with AD also received the DHA+ARA supplement, but were not
randomised to the placebo. The duration of the study was 90 days. The statistical analyses consisted
of within-group comparisons of changes from baseline to the end of the study. Between-group
comparisons were not reported. As for the previous study (Johnson et al., 2008), the applicant was
requested to provide a statistical analysis of the data which is appropriate for placebo-controlled
designs, but no such analysis was provided by the applicant. The Panel considers that no conclusions
can be drawn from this study for the scientiﬁc substantiation of the claim.
The remaining 12 human intervention studies are discussed below. The studies were performed
with DHA derived from microalgae (n = 2), ﬁsh oil (n = 9) and with PS-DHA (n = 1).
3.3.1.1. Human intervention studies performed with DHA derived from microalgae
Yurko-Mauro et al. (2010) conducted a double-blind, parallel, multi-centre RCT on the effects of
DHA on episodic and working memory in healthy older adults with age-related cognitive decline
(ARCD). The Diagnostics and Statistical Manual (DSM-IV) deﬁnes ARCD as an ‘objectively identiﬁed
decline in cognitive functioning consequent to the aging process that is within limits given a person’s
age. Individuals may report problems remembering names or appointments or may experience
DHA and improvement of memory function
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difﬁculty solving complex problems’ (American Psychiatric Association, 1994). ARCD was identiﬁed as a
baseline immediate or delayed recall score ≥ 1 SD below the mean of adults aged 25–35 years on the
Logical Memory subtest of the Wechsler Memory Scale (WMS Version III, 1997). A total of
485 participants aged ≥ 55 years with ARCD (282 female, 203 male) were recruited at 19 study sites.
Participants were excluded if they had a MMSE score < 26, or a mean daily consumption of > 200 mg
DHA in the 2 months before randomisation. Participants were randomised to consume 900 mg of
either DHA (single cell oil from Schizochytrium sp.) or placebo (50% corn oil/50% soy oil) daily for
24 weeks. All supplement capsules were orange ﬂavoured, and identical in size and appearance. The
mean age for both groups was 70 years. Episodic memory was assessed by the Cambridge
Neuropsychological Test Automated Battery (CANTAB) Paired Associate Learning Test (PAL), the
CANTAB Pattern Recognition Memory (PRM) test and the CANTAB Verbal Recognition Memory (VRM)
test (Robbins et al., 1994). Working memory was assessed by the CANTAB Spatial Working Memory
(SWM) test. Assessments were undertaken at baseline, 12 and 24 weeks. A power calculation for
PAL 6 pattern error scores indicated that a total of 325 participants were needed to detect an effect
size of 0.19, with an a-level of 0.05 and a power of 80%, considering a 10% dropout rate. CANTAB
scores at 24 weeks were analysed by ANCOVA with factors of treatment (DHA; placebo), site, age
group (55–69 years; ≥ 70 years) and education. Baseline scores were included as covariate. A total of
437 participants completed the study. Results of the intention-to-treat (ITT) analysis (with the last
observation carried forward for missing data) showed that the DHA group had signiﬁcantly fewer PAL
6 pattern errors at week 24 compared to the placebo group (p = 0.032). The DHA group also had
more VRM correct responses for both immediate recall (p = 0.018) and delayed recall (p = 0.012).
There were no signiﬁcant treatment group differences for either PRM performance or SWM
performance. The Panel notes that this study shows a positive effect of consuming 900 mg of DHA per
day for 24 weeks on episodic memory, but not on working memory, in older adults with ARCD.
Benton et al. (2013) conducted a double-blind, parallel RCT on the effects of DHA on episodic and
semantic memory in 305 females (mean age 21.8 years), who were assigned to consume either
400 mg of DHA (derived from Crypthecodinium cohnii) or placebo (corn oil) per day for 50 days. The
study was conducted in two phases, with one half of the participants taking part 3 months after the
ﬁrst half. Episodic memory was assessed by a recall of word list test in which three matched lists of
30 nouns were created for the study. The test involved presentation of a list at the rate of one word
per second, with recall measured by participants writing down as many of the words they could
remember in a 2-min period. Measures of both immediate and delayed (25 min) recall were obtained
at baseline, 25 days and 50 days. Semantic memory was measured by a recall of capitals test in which
participants were asked to name the capital cities of 30 countries. When a capital could not be
recalled, participants rated their ‘feeling of knowing’ on a 6-point scale. The test was administered
twice at the 50-day assessment, but only to half of the participants (i.e. those taking part in the
second phase of the study). No power calculation was reported. A total of 285 participants completed
the trial and were included in the analyses. The Panel notes that data analyses were provided for the
population of completers only. Results for episodic memory were analysed by three-way repeated-
measures (RM)-ANOVA with factors of treatment (DHA; placebo), time (baseline, day 25, day 50) and
recall time (immediate; delayed). Results are reported as means  SEM. There was a signiﬁcant three-
way interaction for recall of word lists (F(2,566) = 4.41, p < 0.01), with more words forgotten by the
DHA group (3.2  0.19) than by the placebo group (2.6  0.19, p < 0.01) at the end of the study.
There were no signiﬁcant between-group differences for the semantic memory recall of capitals test.
The Panel notes that this study shows a negative effect of consuming 400 mg/day of DHA for 50 days
on episodic memory and no effect on semantic memory in young adults.
3.3.1.2. Human intervention studies performed with DHA from ﬁsh oil
Karr et al. (2012) conducted a double-blind, parallel RCT on the effects of DHA and EPA on episodic
memory in 43 college students (29 female), who received either 2,000 mg ﬁsh oil (480 mg DHA,
720 mg EPA) or 2,000 mg placebo (coconut oil) per day for 4 weeks. Episodic memory was assessed
with the Rey Auditory Verbal Learning Test (RAVLT) (Lezak, 1995) which was administered at baseline
and again after 4 weeks. The test involved completion of seven stages in which participants recalled
words from a list of 15 (List A) which were read out to them. Stages 1–5 involved ﬁve presentations of
List A, each followed by immediate recall. This was followed by an interference trial involving
presentations and recall of a second list (List B). Stage 6 entailed recall of the original List A after the
interference effects of List B, and in stage 7 participants recalled List A after a 20-min delay.
Performance was measured by the number of correctly recalled words on stages 1–7, and by two
DHA and improvement of memory function
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summary measures calculated by subtracting the number of words correct on stage 5 from the
number correct on stages 6 and 7. No power calculations were reported. Results for episodic memory
were analysed by RM-ANOVA with factors of treatment (ﬁsh oil; placebo), time (baseline, week 4) and
varying numbers of RAVLT stages (stages 1–5, stage 6, stage 7, summary measure 7-5 and summary
measure 6-5). Two participants, one from each study group, were removed from the analyses due to
‘problems with following supplementation procedures’. The Panel notes that data analyses were
provided for the population of completers (n = 41) only. There were no signiﬁcant differences between
groups for stages 1–5. Treatment 9 time interactions for stage 6 (F(1,39) = 4.45, p = 0.04) and stage
7 (F(1,39) = 5.65, p = 0.02) were both statistically signiﬁcant. A signiﬁcant treatment 9 time
interaction was also found for the summary measure 7-5 (F(1,39) = 4.30, p = 0.045). Post hoc
comparisons to assess at which time point the intervention and control groups differed regarding the
RAVLT scores were not performed. The applicant was therefore requested to provide post hoc analyses
of the signiﬁcant treatment 9 time interactions which would establish whether the ﬁsh oil group
achieved signiﬁcantly better memory performance than the placebo group at the end of the period of
supplementation. In reply, the applicant referred to the signiﬁcant treatment 9 time interactions as
reported in the publication but did not provide any further analyses. The Panel notes that, for each
signiﬁcant time 9 treatment interaction, performance of the ﬁsh oil group improved across the
duration of the study, while performance of the control group declined (RAVLT scores (mean  SD) for
stages 6 and 7 at baseline: placebo = 11.57  2.36 and 11.48  2.96, respectively, and ﬁsh
oil = 9.85  3.28 and 10.00  3.43, respectively; at week 4: placebo = 11.33  2.06 and
10.29  3.26, respectively, and ﬁsh oil = 10.80  3.14 and 10.50  3.61, respectively). However, the
Panel also notes that the apparent differences in the RAVLT scores between the ﬁsh oil and the
placebo groups at baseline, rather than a real treatment effect, may have driven the time 9 treatment
interactions. The Panel considers that no conclusions can be drawn from this study for the scientiﬁc
substantiation of the claim.
Sinn et al. (2012) performed a double-blind, parallel RCT on the effects of DHA-rich and EPA-rich ﬁsh
oils on episodic memory, short-term memory, working memory and semantic memory in 50 volunteers
aged > 65 years (16 female) with MCI, deﬁned as signs of cognitive decline beyond those expected for
age, but not dementia. Participants were randomly allocated to receive daily either
EPA-rich ﬁsh oil (0.16 g DHA, 1.67 g EPA; n = 17), DHA-rich ﬁsh oil (1.55 g DHA, 0.40 g EPA; n = 18) or
placebo (safﬂower oil providing 2.2 g linolenic acid; n = 15) for 6 months. The mean ages of the three
randomised groups ranged from 73 to 74.9 years. Episodic memory was assessed by the RAVLT. Short-
term memory was assessed with the Digits Forward subtest of the Wechsler Adult Intelligence Scale
(WAIS) (Wechsler, 1997), and working memory was assessed with the Digits Backward subtest of the
WAIS. Semantic memory was assessed by the Boston Naming Task (Lezak, 1995) and verbal ﬂuency test
(Bryan et al., 1997) in which participants produced as many words as possible in 1 min either beginning
with a designated letter (Initial Letter Fluency) or not containing a designated letter (excluded letter
frequency). Memory was assessed at baseline and again at the end of the study. In the publication, it is
reported that, ‘according to Cohen’s f, the required n to detect a medium effect size (d = 0.50) in a RM
within–between interaction design for three groups with a power of 0.80 is 66 participants (22 per
group)’. From this description, the Panel is unclear as to which variable was used for power calculations
and how these calculations were performed. A total of 40 subjects completed the study (control group
n = 11; DHA-group n = 16; EPA-group n = 13). Linear mixed models were used to analyse the effects of
DHA-rich or EPA-rich ﬁsh oil vs. placebo in the ITT population (n = 50). The application of a linear
multilevel model was considered appropriate for the pattern of missing values. All information could be
used and predicted values could be obtained for all participants at each time point. Only Initial Letter
Fluency scores (semantic memory) signiﬁcantly improved in the DHA-rich ﬁsh oil group compared with
the placebo group (p = 0.04). The EPA-rich ﬁsh oil and placebo groups did not differ signiﬁcantly. There
were no signiﬁcant effects involving any of the other memory measures. The Panel notes that no
correction of the signiﬁcance level was made to take into account multiple comparisons. The
Panel considers that this study with a daily consumption of 1.55 g DHA from ﬁsh oil for 6 months did not
show an effect on episodic, short-term, working or semantic memory in subjects with MCI.
Jackson et al. (2012) conducted a double-blind RCT on the effects of DHA-rich and EPA-rich ﬁsh oils
on episodic memory, working memory and semantic memory in 159 volunteers. Participants were
randomly allocated to receive a daily intake of EPA-rich ﬁsh oil (200 mg DHA, 300 mg EPA), DHA-rich
ﬁsh oil (450 mg DHA, 90 mg EPA) or placebo (olive oil) for 12 weeks. Mean ages of the three
randomised groups ranged from 21.9 to 22.7 years. Episodic memory was assessed by tests of
Immediate Word Recall, Delayed Word Recall, Delayed Word Recognition, Delayed Picture Recognition
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and Names-to-Faces Recall. Working memory was assessed by tests of Numeric Working Memory,
Alphabetic Working Memory, SWM (Corsi Blocks), Three-back Task and Telephone Number Working
Memory. Semantic memory was assessed by a test of verbal ﬂuency. All tests were taken from the
Computerised Mental Performance Assessment System (url: http://www.cognitivetesting.co.uk/).
Memory was assessed at baseline and again at the end of the study. Data were analysed by one-way
between-subject (treatment group) ANCOVA, with data from the relevant outcome measure at
baseline as covariate. A priori planned comparisons using t-tests were made between placebo and
both the DHA-rich ﬁsh oil and EPA-rich ﬁsh oil groups. A total of 140 subjects were compliant with the
study protocol and entered data analyses (control group = 48, DHA-group = 46, EPA-group = 46). The
Panel notes that data analyses were provided for the per protocol (PP) population only. There was a
treatment effect for Names-to-Faces Recall (F(2,136) = 3.73, p = 0.026), with participants in both the
DHA-rich ﬁsh oil group and EPA-rich ﬁsh oil group showing fewer correct matches than the placebo
group (p = 0.047 and 0.013, respectively). There were no signiﬁcant effects for any of the remaining
memory tests. The Panel notes that no adjustment to the signiﬁcance level was made to take into
account the multiple comparisons. The Panel considers that this study with a daily consumption of
450 mg DHA from ﬁsh oil for 12 weeks did not show an effect on episodic, working or semantic
memory in young adults.
Dangour et al. (2010) completed a double-blind, parallel RCT on the effects of DHA on episodic
memory, working memory and semantic memory in 867 cognitively healthy adults aged between
70 and 79 years (390 female). Participants were randomly allocated to receive a daily intake of ﬁsh oil
(500 mg DHA, 200 mg EPA) or placebo (olive oil) for 24 months. Episodic memory was assessed by
the California Verbal Learning Test (CVLT; including a test of memory of a 16-item word list) (Delis
et al., 1987), immediate and delayed recall of a short story taken from the WMS (Wechsler, 1987), a
test of spatial memory (van Niekerk et al., 2004) and three tests of prospective memory (Maylor,
1993). Working memory was assessed with the Digits Backward subtest of the WAIS (Wechsler, 1981),
and semantic memory was assessed by a verbal ﬂuency test (Goodglass and Kaplan, 1983).
Short-term memory was assessed with the Digits Forward subtest of the WAIS. Memory tests were
administered twice, at baseline and again at the end of the study. A composite episodic memory score
was calculated by summing z-scores for the CVLT, location memory and story recall measures. All other
memory measures were included in a global cognitive function composite score which included several
other non-memory measures such as processing speed, reaction time and executive function.
Therefore, the Panel considers that no conclusions can be drawn from this global cognitive function
composite score for the scientiﬁc substantiation of the claim. A power calculation indicated that a total
of 332 participants were required per group to detect a 0.3 SD difference in delayed free recall of a
16-item word list between treatment groups. Data were analysed by one-way between-subject
(treatment group) ANCOVA, with data from the baseline as the covariate, as well as age, sex and age
at leaving full-time education. A total of 748 participants completed the study, with cognitive function
data available for 744 participants (ﬁsh oil group = 375, control group = 369). The Panel notes that
data analyses were provided for the population of completers only. There were no signiﬁcant
differences between treatment groups for the total words correct in the ﬁrst three CVLT trials, or the
number of words recalled in CVLT delayed recall. There were no signiﬁcant differences between groups
in the composite memory scores at 24 months. The Panel notes that the daily consumption of 500 mg
DHA from ﬁsh oil for 24 months did not have an effect on episodic, short-term, working or semantic
memory in cognitively healthy older adults.
Lee et al. (2013) conducted a double-blind RCT on the effects of ﬁsh oil supplementation on
episodic memory, working memory and short-term memory in participants with MCI. A total of
36 elderly participants with MCI (27 female) were randomly allocated to receive a daily dose of
DHA-rich ﬁsh oil (1.29 g DHA, 450 mg EPA) or placebo (corn oil, providing 1.8 g linolenic acid) for
12 months. Episodic memory was assessed by the RAVLT, and two subtests from the Wechsler
Memory Scale-Revised (WMS-R) (Wechsler, 1984). Working memory was assessed with the Digit Span
Backward subtest of the WAIS (Wechsler, 1997), and short-term memory was assessed with the Digit
Span Forward subtest of the WAIS. Memory was assessed at baseline, 6 months and 12 months. No
power calculation was reported. Changes in memory scores for individual tests were assessed using
RM-ANCOVA, with factors of treatment (ﬁsh oil; placebo) and time (baseline; 12 months) and
covariates of baseline age, baseline systolic and diastolic blood pressure, and years of schooling.
Bonferroni corrections were used for multiple comparisons in post hoc analyses of all
neuropsychological tests. There were signiﬁcant treatment 9 time interactions for digit span (F = 9.89;
p < 0.0001) and RAVLT delayed recall (F = 3.99; p < 0.05). Absolute data were provided as means
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and 95% CI (digit span, placebo, baseline: 8.5 (7.554–9.529), 6 months: 8.4 (7.242–9.472),
12 months: 8.0 (6.877–9.113); ﬁsh oil group, baseline: 8.0 (6.994–9.036), 6 months: 8.2 (7.058–9.363),
12 months: 9.6 (8.437–10.749)); RAVLT delayed recall, placebo, baseline: 6.1 (4.431–7.860), 6 months:
6.4 (4.687–8.052), 12 months: 5.0 (3.587–6.312); ﬁsh oil group, baseline: 6.7 (4.897–8.442), 6 months:
6.1 (4.399–7.878), 12 months: 8.1 (6.645–9.462). There were no signiﬁcant effects involving any of the
other memory tests. A composite memory score was calculated by the authors by averaging z-scores for
the RAVLT, WMS-R and Digit Span Backward tests. Changes in memory performance from baseline to
12 months were calculated for this composite memory score, and the change was signiﬁcantly better for
the ﬁsh oil group than the placebo group (difference between groups in composite z-score: 0.799, 95%
CI: 0.339–1.258, p < 0.01). The Panel considers that this study showed an improvement of memory
function with a daily consumption of 1.29 g DHA from ﬁsh oil for 12 months in adults with MCI.
Stonehouse et al. (2013) reported the ﬁndings of a double-blind, parallel RCT of the effects of DHA
supplementation on episodic and working memory. A total of 228 healthy adults (145 female) aged
between 18 and 45 years and with a ‘low’ dietary intake of DHA (i.e. less than about 200 mg
EPA+DHA/week) were randomly allocated to receive ﬁsh oil (1.16 g DHA, 0.17 g EPA) or placebo (high
oleic acid sunﬂower oil) daily for 6 months. Episodic memory was assessed by tests of Immediate
Word Recall, Delayed Word Recall, Delayed Word Recognition and Delayed Picture Recognition.
Working memory was assessed by tests of Letter-Number Sequencing, SWM (Corsi Blocks) and n-back
Tasks. All tests were taken from the Computerised Mental Performance Assessment System. Memory
was assessed at baseline and again at the end of the study. Composite memory scores were calculated
by obtaining the average of the z-scores for individual memory tests. The composite scores included
memory, working memory, reaction time of memory and reaction time of working memory. Power
calculations indicated that a total of 32 participants per sex and treatment group were required to
detect a difference in z-score of 0.5 ‘for memory domains’ at a power of 0.8 at a signiﬁcance level of
0.05. Changes in memory during the treatment period between ﬁsh oil and placebo groups were
assessed by using ANCOVA models to adjust for baseline cognitive function test scores and other
covariates, as follows: education, ﬁrst language (English compared with other), age and baseline blood
DHA concentrations. Sex and presence of the apolipoprotein E4 (APOE4) allelic variant were added as
independent variables to test for sex 9 treatment, APOE 9 treatment, and APOE 9 sex 9 treatment
interactions. A total of 176 participants (n = 85 in the DHA group (52 women); n = 91 in the placebo
group (58 women)) completed the trial and were included in the analyses. Dropouts did not differ
signiﬁcantly from the participants who completed the study for any baseline characteristic except age.
The Panel notes that data analyses were provided for the population of completers only. The
sex 9 treatment interaction for episodic memory was signiﬁcant (p = 0.01), with women in the DHA
group showing a greater improvement compared to placebo (p = 0.01), but no signiﬁcant differences
between groups were observed for men (p = 0.20). There was a signiﬁcant treatment effect for
reaction time of episodic memory, with the DHA group responding faster than placebo, but the
sex 9 treatment effect was not signiﬁcant. There was a similar effect of treatment for reaction time of
working memory with the DHA group responding faster than placebo (p = 0.002). The
sex 9 treatment interaction was also signiﬁcant (p = 0.03) with men in the DHA group completing the
task faster than men in the placebo group (p = 0.001), but no signiﬁcant difference was reported for
women (p = 0.39). There were no signiﬁcant effects for working memory. APOE4 status did not affect
treatment responses for any memory outcome. The Panel notes that in this study with a consumption
of 1.16 g/day DHA from ﬁsh oil for 6 months, a number of improvements were observed on episodic
and working memory in healthy adults, but these effects were inconsistent among tests and sexes.
The Panel considers that this study does not show consistent effects of DHA consumption on memory.
Stough et al. (2012) completed a triple-blind, parallel RCT of DHA in tuna oil on episodic and
working memory. A total of 112 healthy adults aged 45–80 years were randomly assigned to receive
daily DHA-rich ﬁsh oil (252 mg DHA, 60 mg EPA) or placebo (soybean oil) for 90 days. The
Panel notes that no demographic data were provided for the ITT population (n = 112), but only for the
PP population (n = 74). Episodic memory was assessed by tests of Immediate Word Recall, Delayed
Word Recall, Delayed Word Recognition and Delayed Picture Recognition. Working memory was
assessed by tests of SWM and Numeric Working Memory. All tests were taken from the cognitive drug
research (CDR) computerised assessment system (Wesnes et al., 1999). The individual measures were
used to calculate CDR factor scores for Speed of Memory, Secondary Memory and Working Memory.
Memory tests were administered at baseline and again at the end of the study. Post hoc power
calculations indicated that, with a sample size of 74 participants and an a-level of 0.05, there was a
99% chance of detecting a ‘medium’ effect size (f = 0.25) but only a 40% chance of detecting a ‘small’
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effect size (f = 0.1) ‘on cognition’. The Panel notes that the outcome variable was not further speciﬁed.
Nineteen participants withdrew during the course of the trial. A further 19 participants were removed
because of inadequate compliance (i.e. < 90%). The remaining 74 participants (ﬁsh oil = 38;
placebo = 36) were included in the ﬁnal analyses. The Panel notes that data analyses were provided
for the PP population only. Mixed-design RM-ANCOVA, with time (baseline vs. post-treatment) as the
within-subjects factor and treatment group (DHA vs. placebo) as the between-subjects factor, and age
as a covariate, were conducted on all cognitive outcomes. There were no signiﬁcant effects for any of
the memory measures. The Panel notes that the consumption of 252 mg/day DHA in ﬁsh oil for
90 days did not have an effect on episodic or working memory in healthy adults.
The double-blind, three-arm, parallel RCT of Van de Rest et al. (2008) investigated the effect of ﬁsh
oil supplementation for 26 weeks on measures of episodic memory, working memory, semantic
memory and short-term memory. A total of 302 cognitively healthy participants (135 female) with a
mean age of 70 years and MMSE scores > 21 were randomised to consume daily a ‘high dose’ of ﬁsh
oil providing 847  23 mg DHA and 1,093  17 mg EPA, a ‘low dose’ of ﬁsh oil providing 176  4 mg
DHA and 226  3 mg EPA, or placebo (mainly oleic acid). Episodic memory was assessed by the Word
Learning Test (Van der Elst et al., 2005), working memory with the Digits Backward subtest of the
WAIS (Wechsler, 1981), short-term memory with the Digits Forward subtest of the WAIS and semantic
memory with the Verbal Fluency Test (Van der Elst et al., 2005). A composite memory score was
calculated as the mean of the z-scores for Immediate and Delayed Word Learning, Word Learning
Recognition and Backward Digit Span. Assessments were undertaken three times (at baseline and after
13 and 26 weeks). A power calculation based on the Word Learning Test required a minimum of
63 participants per group to detect a difference of 4 points with a power of 80% and an a-level of
0.05. RM-ANOVA was used to test differential changes among the three intervention groups after 13
and 26 weeks, with the treatment group as the factor and scores on the memory composite and
short-term memory test as the dependent variables. A Dunnett’s post hoc test was conducted to
compare mean changes in the two treatment groups with changes in the control group. There
were no signiﬁcant effects of treatment at any time point. The Panel notes that the consumption of
850 mg/day DHA in ﬁsh oil for 26 weeks did not have an effect on episodic, working, short-term or
semantic memory in cognitively healthy older adults.
The double-blind, parallel RCT of Witte et al. (2013) examined the effect of DHA and EPA
supplementation on measures of episodic memory, working memory, semantic memory and short-term
memory. A total of 65 healthy participants (30 female) aged 50–75 years were randomised to receive
either ﬁsh oil (880 mg DHA, 1,320 mg EPA) or placebo (sunﬂower oil) daily for 26 weeks. The mean
ages of the two groups were not signiﬁcantly different (DHA+EPA = 65 years; placebo = 62.9 years),
and all participants had a MMSE score > 26. Episodic memory was assessed by the Auditory Verbal
Learning Test (AVLT) (Lezak, 2004), which included measures of immediate and delayed recall, as well
as recognition. Working memory was assessed with the Backward Digit Span Test, and short-term
memory with the Forward Digit Span Test (Lezak, 2004). Semantic memory was assessed with the
Verbal Fluency Test (Lezak, 2004). A composite memory score was calculated by averaging z-scores
for AVLT learning, delayed recall, recognition and digit span backward. No power calculations
were reported. Results were analysed with a RM-ANOVA with factors of treatment (ﬁsh oil; placebo)
and time (baseline; week 26), and Bonferroni corrections for multiple comparisons. There were
no signiﬁcant effects for the composite memory score, and no signiﬁcant effect of treatment on
short-term memory. The Panel notes that the consumption of 880 mg/day DHA in ﬁsh oil for 26 weeks
did not have an effect on episodic, working, semantic or short-term memory in healthy adults.
3.3.1.3. Human intervention study performed with PS-DHA
Vakhapova et al. (2010) examined the effects of PS-DHA on measures of episodic memory, working
memory and short-term memory in 157 (78 female) non-demented elderly participants with memory
complaints. Inclusion criteria were complaints of memory loss in everyday life as conﬁrmed by a score
of ≥ 25 on the Memory Complaint Questionnaire scale (Crook et al., 1992); absence of dementia as
determined by a MMSE score ≥ 27 for participants with college education and ≥ 26 for all others, and
a Clinical Dementia Rating Scale score ≤ 0.5; and scores in NexAde computerised cognitive assessment
tool ≤ the mean norm (Aharonson and Korczyn, 2004). Participants were randomly assigned to receive
PS-DHA (providing 300 mg PS and 79 mg DHA+EPA (DHA/EPA ratio of 3:1)) or placebo (cellulose)
daily for 15 weeks. The mean age of both groups was 73 years. Episodic memory was assessed by the
RAVLT, Rey Complex Figure Test (RCFT) (Meyers and Meyers, 1995), and immediate and delayed
pattern recall tasks from the NexAde battery. Working memory was assessed with a digit span
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backward task, and short-term memory with a digit span forward task, both from the NexAde battery.
NexAde memory composite scores were calculated from the individual tests: memory recognition and
recall (episodic memory), and spatial short-term memory. Assessments were undertaken twice, at
baseline and at the end of the study. No power calculation was reported. Changes were examined with
ANCOVA, which included baseline performance and MMSE scores as covariates. A total of 131 subjects
completed the study (n = 66 in the PS-DHA group; n = 65 in the placebo group). Nine further subjects
(six from the placebo group and three from the PS-DHA group) were excluded from the analyses for
lack of compliance (i.e. < 65%). The Panel notes that data analyses were provided for the PP
population (n = 122) only, with the exception of the immediate recall scores, which were provided for
the PP population and the completers (n = 131). At 15 weeks, immediate recall scores in the RAVLT
were signiﬁcantly higher (p = 0.041) in the PS-DHA group compared to the placebo group in the PP
population but not in the population of completers. There were no signiﬁcant effects on any other
RAVLT outcomes (i.e. total learning, delayed recall and recognition) or the RCFT. No adjustment to the
signiﬁcance level was made to take into account the multiple comparisons. No statistically signiﬁcant
differences between the groups were observed for any of the NexAde tasks, including tests for
working memory and short-term memory. The Panel notes that, in this study, only one out of four
RAVLT outcomes was signiﬁcantly higher in the PS-DHA than in the placebo group (in the PP
population only), that no correction for multiple comparisons was applied, and that there were no
statistically signiﬁcant differences for working memory or short-term memory. The Panel considers
that, overall, this study with a consumption of DHA taken as PS-DHA for 15 weeks did not show an
improvement of memory function.
The Panel notes that out of the 11 intervention studies from which conclusions can be drawn for
the scientiﬁc substantiation of the claim, two were performed with DHA from microalgae, eight with
DHA from ﬁsh oil and one with PS-DHA. One study conducted with DHA from algal oil showed an
improvement in episodic memory but not in working memory in healthy older adults with ARCD after
consumption of 900 mg DHA for 24 weeks (Yurko-Mauro et al., 2010), while the other study with DHA
from the same source showed a negative effect on episodic memory and no effect on semantic
memory in young adults after consumption of 400 mg DHA for 50 days (Benton et al., 2013). Out of
the eight intervention studies performed with DHA from ﬁsh oil, which provided daily doses of DHA
ranging from 252 mg to 1.55 g for periods between 12 weeks and 24 months, only one showed an
improvement in memory in adults with MCI (Lee et al., 2013), while the results from another study
were inconsistent (Stonehouse et al., 2013) and six studies did not show an effect of DHA
supplementation on memory outcomes (Van de Rest et al., 2008; Dangour et al., 2010; Jackson et al.,
2012; Sinn et al., 2012; Stough et al., 2012; Witte et al., 2013). The study which used PS-DHA did not
show an effect of the food on memory function (Vakhapova et al., 2010). The Panel considers that the
majority of the human intervention studies provided did not show an effect of DHA supplementation
on memory, and that the conﬂicting results across studies cannot be explained by differences in the
study design, the source of DHA, the DHA dose, the baseline characteristics of the subjects recruited,
the sample size or the duration of the studies.
3.3.2. Meta-analyses as provided by the applicant
The applicant conducted meta-analyses using data from the 15 intervention studies described in
the previous section. These meta-analyses (partly published by Yurko-Mauro et al., 2015) summarised
62 data points for episodic memory, 15 data points for semantic memory and 21 data points for
working memory. Both between-group (differences from placebo) and within-group (differences from
baseline) comparisons were provided for episodic, semantic and working memory. Random effects
meta-analyses were conducted to generate weighted group mean differences and Hedge’s g scores,
which standardised the weighted group mean differences by the pooled standard deviation of the
studies. The studies included in the meta-analyses were conducted in healthy subjects without (n = 9
studies) and with (n = 6 studies) mild memory complaints, ranged from 28 to 730 days in duration
(average 4–6 months), were mostly (n = 11 studies) conducted with older adults (45–80 years of age),
provided up to 1.55 g DHA/day and had a sample size of 8–867 subjects.
The overall between-group models, which included all dose levels of DHA, all sources of DHA and
all subjects regardless of their age or cognitive status at baseline, showed no effect of DHA
supplementation on episodic, semantic or working memory.
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Sensitivity analyses considering age, baseline cognitive status and DHA dose levels were also
provided. However, the Panel considers that the results from those analyses were inconsistent and
provided no clear evidence for an effect of DHA on memory function.
The Panel considers that these meta-analyses do not provide evidence for an effect of DHA on
memory function.
3.3.3. Observational studies
The applicant provided 13 observational studies as pertinent to the claim (Kalmijn et al., 2004;
Whalley et al., 2004; Beydoun et al., 2007; de Groot et al., 2007; Dullemeijer et al., 2007; Whalley
et al., 2008; Muldoon et al., 2010; Kesse-Guyot et al., 2011; Milte et al., 2011; Samieri et al., 2011;
Phillips et al., 2012; Tan et al., 2012; Titova et al., 2013).
Among the references provided, nine studies (Beydoun et al., 2007; de Groot et al., 2007; Dullemeijer
et al., 2007; Whalley et al., 2008; Muldoon et al., 2010; Milte et al., 2011; Samieri et al., 2011; Phillips
et al., 2012; Tan et al., 2012) did not report on dietary intakes of DHA but addressed the association
between blood concentrations of DHA and measures of memory. One study (Titova et al., 2013) reported
only a composite cognitive score but no independent memory test scores. The Panel considers that no
conclusions can be drawn from these studies for the scientiﬁc substantiation of the claim.
Three studies (Kalmijn et al., 2004; Whalley et al., 2004; Kesse-Guyot et al., 2011) addressed the
association between dietary intakes of DHA or ﬁsh oil supplements and measures of memory. Kalmijn
et al. (2004) completed a cross-sectional study with 1,613 participants aged between 45 and 70 years
and found no signiﬁcant association between DHA+EPA intake and risk of episodic memory
impairment. Whalley et al. (2004) completed a cross-sectional study with 301 participants aged
64 years and found no signiﬁcant difference in episodic memory scores between ﬁsh oil users and ﬁsh
oil nonusers. Kesse-Guyot et al. (2011) completed a prospective cohort study with 3,294 adults aged
35–60 years and found no signiﬁcant association between DHA intake and episodic memory scores.
The Panel notes that, in these studies, the consumption of DHA showed no association with episodic
memory in adults.
The Panel considers that the three observational studies from which conclusions can be drawn for
the scientiﬁc substantiation of the claim do not provide evidence for an association between dietary
DHA and memory function.
3.3.4. Weighing of the evidence
In weighing the evidence, the Panel took into account that out of the 11 human intervention
studies from which conclusions can be drawn for the scientiﬁc substantiation of the claim, two studies
showed a beneﬁcial effect of DHA supplementation on memory function, one study showed
inconsistent results, one study showed a negative effect of DHA on memory function and seven
studies did not show an effect of DHA on memory outcomes. The Panel considers that the majority of
the human intervention studies provided did not show an effect of DHA supplementation on memory,
and that the conﬂicting results across studies cannot be explained by differences in the study design,
the source of DHA, the DHA dose, the baseline characteristics of the subjects recruited or the duration
of the studies. The Panel also took into account that the meta-analyses of the intervention studies
submitted by the applicant do not provide evidence for an effect of DHA on memory function, and that
the three observational studies from which conclusions could be drawn for the scientiﬁc substantiation
of the claim do not provide evidence for an association between dietary DHA and memory function.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of DHA and an improvement of memory function.
4. Conclusions
On the basis of the data presented, the Panel concludes that:
• The food constituent, DHA, which is the subject of the health claim, is sufﬁciently characterised.
• The claimed effect proposed by the applicant is ‘contributes to improved memory function’.
The target population proposed by the applicant is ‘the general healthy adult population’. An
improvement of memory function is a beneﬁcial physiological effect.
• A cause and effect relationship has not been established between the consumption of DHA and
an improvement of memory function.
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Steps taken by EFSA
1) Health claim application on DHA, alone or in combination with EPA, and contributes to
improved memory function pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim
serial No: 0438_UK). Submitted by DSM Nutritional Products, 6450 Dobbin Road, Columbia,
MD 21405, USA.
2) The application was received by EFSA on 24 July 2015.
3) The scope of the application was proposed to fall under a health claim based on newly
developed scientiﬁc evidence.
4) The scientiﬁc evaluation procedure started on 15 September 2015.
5) On 30 October 2015, the NDA Panel agreed on a list of questions for the applicant to provide
additional information to accompany the application. The scientiﬁc evaluation was suspended
on 11 November 2015, in compliance with Article 18(3) of Regulation (EC) No 1924/2006.
6) On 20 November 2015, EFSA received the applicant’s reply and the scientiﬁc evaluation was
restarted, in compliance with Article 18(3) of Regulation (EC) No 1924/2006.
7) On 20 January 2016, the Working Group on Claims of the NDA Panel agreed on a list of
questions for the applicant to provide additional information to accompany the application.
The scientiﬁc evaluation was suspended on 5 February 2016, in compliance with Article 18(3)
of Regulation (EC) No 1924/2006.
8) On 18 February 2016, EFSA received the applicant’s reply and the scientiﬁc evaluation was
restarted, in compliance with Article 18(3) of Regulation (EC) No 1924/2006.
9) On 30 March 2016, the NDA Panel, having evaluated the data submitted, adopted by written
procedure an opinion on the scientiﬁc substantiation of a health claim related to DHA and
improved memory function.
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